Patents Issued in January 9, 2018
  • Patent number: 9862723
    Abstract: A stable polymorph (Form Z1) of the salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [152,4]triazolo[4,3-?]pyrazin-7(8H)-yl]-1-(2s4,5-trifluorophenyl)butan-2-amine (sitagliptin) with L-tartaric acid, of formula 1, which is a very suitable form of the active pharmaceutical ingredient of medicinal products intended especially for treatment of diabetes type 2. A method of preparation of the stable polymorph (Form Z1) of the salt of sitagliptin with L-tartaric acid, as well as its use for the preparation of a pharmaceutical composition.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: January 9, 2018
    Assignee: Zentiva k.s.
    Inventors: Jindrich Richter, Petr Lehnert, Kamal Jarrah, Ondrej Dammer, Lukas Krejcik
  • Patent number: 9862724
    Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: January 9, 2018
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: Yingzhi Bi, Michael Walter Gardyan, Michael Alan Green, Godwin Kumi, Yulian Zhang
  • Patent number: 9862725
    Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of, reductive amination of:
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: January 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
  • Patent number: 9862726
    Abstract: The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, Y, Z, and G are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I), and pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 9, 2018
    Assignee: Purdue Pharma L.P.
    Inventor: Mark Youngman
  • Patent number: 9862727
    Abstract: The invention describes a method for degrading off-odors by employing a special 1-aza-3,7-dioxabicyclo[3.3.0]octane compound. Degradation of off-odors to the point of extinction of the off-odor, on hard and/or soft surfaces, in particular on textiles, and in room air, is made possible.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: January 9, 2018
    Assignee: Henkel AG & Co. KGaA
    Inventors: Ursula Huchel, Marc Weyhe, Lukas Baron
  • Patent number: 9862728
    Abstract: Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: January 9, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Dustin Bringley, Johann Chan, Peter Fung, Katie Keaton, Olga Lapina, Henry Morrison, Dominika Pcion
  • Patent number: 9862729
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 9, 2018
    Assignee: GLADIUS PHARMACEUTICALS CORPORATION
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 9862730
    Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: January 9, 2018
    Assignees: Bristol-Myers Squibb Company, Universite De Montreal
    Inventors: R. Michael Lawrence, Michael M. Miller, Dietmar Alfred Seiffert, Shoshana L. Posy, Pancras C. Wong, Jacques Banville, Edward H. Ruediger, Daniel H. Deon, Alain Martel, François Tremblay, Julia Guy, Jean-François Lavallée, Marc Gagnon
  • Patent number: 9862731
    Abstract: The present invention provides a difluoroboron dipyrromethene fluorescent probe having a structure represented by the following general formula I, and a production method and an application thereof. Said difluoroboron dipyrromethene fluorescent probe exhibits low background fluorescence, and a rapid and significant fluorescence enhancement up to 100 times after the addition of hypochloric acid. The fluorescent intensity of said fluorescent probe shows a good linear relation with the concentration of hypochloric acid in a nanomole level, and the detection limit thereof is 0.56 nanomole. Said fluorescent probe has good selectivity since it hardly responds to other reactive oxygen species such as H2O2, O2?, TBHP, HO., TBO., 1O2 and NO., and is not interfered by pH in a wide range. Said fluorescent probe can be applied to detect hypochloric acid in living cells.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: January 9, 2018
    Assignee: DALIAN UNIVERSITY OF TECHNOLOGY
    Inventors: Jiangli Fan, Hao Zhu, Xiaojun Peng, Jingyun Wang
  • Patent number: 9862732
    Abstract: A 1,2-regioselective organolanthanide-catalyzed azine dearomatization process using pinacolborane is disclosed.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 9, 2018
    Assignee: Northwestern University
    Inventors: Tobin J. Marks, Massimiliano Delferro, Alexander S. Dudnik, Victoria L. Weidner
  • Patent number: 9862733
    Abstract: Provided are methods for purifying N-methyliminodiacetic acid (MIDA) boronates from solution. Also provided are methods for deprotection of boronic acids from their MIDA ligands. The purification and deprotection methods can be used in conjunction with methods for coupling or otherwise reacting boronic acids. Iterative cycles of deprotection, coupling, and purification can be performed to synthesize chemical compounds of interest. The methods are suitable for use in an automated chemical synthesis process. Also provided is an automated small molecule synthesizer apparatus for performing automated synthesis of small molecules using iterative cycles of deprotection, coupling, and purification in accordance with methods of the invention.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 9, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Eric P. Gillis, Steven G. Ballmer
  • Patent number: 9862734
    Abstract: A metal-ligand complex has formula (I): wherein J, L, M, R1, R2, R3, R4, X, p, q, and r are defined herein. The metal-ligand complex is useful as a catalyst or catalyst precursor for olefin polymerization.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: January 9, 2018
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Jerzy Klosin, Philip P. Fontaine, Ruth Figueroa, David M. Pearson, Todd D. Senecal
  • Patent number: 9862735
    Abstract: An organosilicon compound having diphenylethyl and methoxysilyl groups is more readily hydrolyzable than ethoxysilyl-containing organosilicon compounds and generates no hydrogen chloride on use.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: January 9, 2018
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Takayuki Honma, Tohru Kubota, Yoichi Tonomura
  • Patent number: 9862736
    Abstract: The present invention relates to a new bimetallic complex of the formula (1) wherein: M is a group 4-6 metal R1 means is a substituent comprising a heteroatom of group 15, through which R1 is bonded to the imine carbon atom; R2-R6 are the same or different and each represents a hydrogen atom, an optionally substituted C1-10 alkyl group, an optionally substituted C1-10 alkoxy group, an optionally substituted C6-20 aryl group, an optionally substituted C6-20 aryloxy group, an optionally substituted C7-20 aralkyl group, an optionally substituted C7-20 aralkyloxy group, a silyl group substituted with optionally substituted C1-20 hydrocarbon group(s), a C1-20 hydrocarbon-substituted amino group or the adjacent R2-R6 may be linked to each other to form a ring; R7-R10 are the same or different and each represents a hydrogen atom, a halogen atom, an optionally substituted C1-10 alkyl group, an optionally substituted C1-10 alkoxy group, an optionally substituted C6-20 aryl group, an optionally substituted C6-20 arylox
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: January 9, 2018
    Assignee: ARLANXEO NETHERLANDS B.V.
    Inventors: Alexandra Berthoud, Victor Quiroga Norambuena, Gerard Van Doremaele, Martin Alexander Zuideveld, Henricus Johannes Arts, Richard Thomas William Scott
  • Patent number: 9862737
    Abstract: In part, the present invention is directed to antibacterial compounds and salts thereof.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: January 9, 2018
    Assignee: Debiopharm International SA
    Inventors: Henry Pauls, Jailall Ramnauth
  • Patent number: 9862738
    Abstract: Novel heterocyclic selenophosphites, method for preparation thereof and use thereof as ligand unit for preparing ligands for use in complexes.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: January 9, 2018
    Assignee: EVONIK DEGUSSA GMBH
    Inventors: Katrin Marie Dyballa, Robert Franke, Detlef Selent, Armin Börner, Claudia Weilbeer
  • Patent number: 9862739
    Abstract: Cyclometallated Ir complex comprising three N,N diaryl substituted carbene ligands, bearing substituents in the 2 position of the non-cyclometallated aryl ring; an organic electronic device, preferably an organic light-emitting diode (OLED), comprising at least one cyclometallated Ir complex as described above, a light-emitting layer comprising said cyclometallated Ir complex preferably as emitter material, preferably in combination with at least one host material, use of said cyclometallated Ir complex in an OLED and an apparatus selected from the group consisting of stationary visual display units, mobile visual display units, illumination units, units in items of clothing, units in handbags, units in accessories, units in furniture and units in wallpaper comprising said organic electronic device, preferably said OLED, or said light-emitting layer. The present invention further relates to a process for the preparation of said cyclometallated Ir complex.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: January 9, 2018
    Assignee: UDC Ireland Limited
    Inventors: Stefan Metz, Korinna Dormann, Glauco Battagliarin, Christian Eickhoff, Flavio Luiz Benedito, Soichi Watanabe, Gerhard Wagenblast, Thomas Geβner, Christian Lennartz, Peter Murer
  • Patent number: 9862740
    Abstract: The present invention relates to a process for obtaining Tiacumicin B with a well defined crystal habit and particle size. The process according to the invention comprises repeating cycles of heating and cooling under controlled conditions of temperature and stirring.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: January 9, 2018
    Assignee: OLON S.P.A.
    Inventors: Piera Fonte, Giovanni Lazzari
  • Patent number: 9862741
    Abstract: The present disclosure provides cytidine derivative dimers, salts and compositions of the cytidine derivative dimers, and methods of making and using the cytidine derivative dimers. The compounds that useful for treating a neoplasm in mammalian subjects. The cytidine derivative dimer has the following general formula (I): where R1 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R2 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R3 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; R4 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; and R5 is —(CH2)n—, substituted —(CH2)n—, or —(CH2)n—X1—X2—, X1 being O or S, and X2 being —(CH2)n-Ph, pyrimidyl, pyranyl, imidazolyl, pyrazinyl, or pyridyl. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 9, 2018
    Assignees: CHANGZHOU PANGYUAN PHARMACEUTICAL CO., LTD, INNER MONGOLIA PUYIN PHARMACEUTICAL CO., LTD
    Inventors: Daria Yang, Haidong Wang, Hui-Juan Wang
  • Patent number: 9862742
    Abstract: The present invention provides fluorine substituted tricyclic nucleosides of formula (I) wherein: the substituents are as defined in the claims. The present invention further provides oligomeric compounds prepared therefrom. Incorporation of one or more of the tricyclic nucleosides into an oligomeric compound enhances one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in double stranded compositions.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Assignee: UNIVERSITÄT BERN
    Inventor: Christian Leumann
  • Patent number: 9862743
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: January 9, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Marija Prhavc, Christian Andreas Jekle, Jerome Deval
  • Patent number: 9862744
    Abstract: A method of treating a patient to reduce risk of developing Clostridium difficile-associated disease or reducing existing Clostridium difficile-associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: January 9, 2018
    Assignee: THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS
    Inventors: Ernesto Abel-Santos, Amber Howerton
  • Patent number: 9862745
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 9, 2018
  • Patent number: 9862746
    Abstract: The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: January 9, 2018
    Assignee: The Regents of the University of Michigan
    Inventors: Zaneta Nikolovska-Coleska, Chenxi Shen, Jay Hess
  • Patent number: 9862747
    Abstract: The invention relates to a peptide compound and its pharmaceutical composition for inhibiting platelet aggregation and preventing/treating thrombogenic diseases. The invention develops pentapeptides and hexapeptides derived from snake venom C-type lectin-like proteins (CLPs) fragments, which can inhibit platelet aggregation and have antithrombotic activity without hemorrhagic tendency. Accordingly, they can be used as potential agents for the prevention and therapy of thrombogenic diseases.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: January 9, 2018
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Tur-Fu Huang, Chien-Hsin Chang, Ching-Hu Chung
  • Patent number: 9862748
    Abstract: Peptide compounds based on the CAP37 (cationic antimicrobial protein of Mr 37 kDa) protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: January 9, 2018
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Heloise Anne Pereira
  • Patent number: 9862749
    Abstract: The present invention relates to a novel analogue antibiotic peptide derived from a CM-MA peptide and a use thereof. Specifically, the novel antibiotic peptides represented by SEQ. ID. NO: 2 to SEQ. ID. NO: 7 (CAM 1 to CMA 6) were synthesized by using a CM-MA antibiotic peptide, in which amphiphilic cecropin A (CA) and magainin 2 (MA) are conjugated, as a template. The synthesized antibiotic peptide exhibits antibiotic activity on gram-positive bacteria and gram-negative bacteria and low cytotoxicity on human red blood cells and human normal cell lines (HaCaT), and thus the antibiotic peptide of the present invention can be favorably used as an active ingredient of an antibiotic agent, a cosmetic composition, a food additive, a feed additive, and a biological pesticide.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: January 9, 2018
    Assignee: Industry-Academic Cooperation Foundation, Chosun University
    Inventor: Yoonkyung Park
  • Patent number: 9862750
    Abstract: The invention provides a chaperone/usher family polymer comprising at least one chaperone/usher family polypeptide monomer, wherein said at least one chaperone/usher family polypeptide monomer comprises an exogenous bioactive sequence.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: January 9, 2018
    Assignee: University of Newcastle Upon Tyne
    Inventor: Jeremy Lakey
  • Patent number: 9862751
    Abstract: There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises a portion of the region 40-60 of myelin oligodendrocyte glycoprotein (MOG). In particular there is provided an apitope which is selected from the following myelin oligodendrocyte glycoprotein peptides: MOG 41-55, 43-57, 44-58 and 45-59. There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: January 9, 2018
    Assignee: APITOPE TECHNOLOGY (BRISTOL) LIMITED
    Inventors: David Wraith, Heather Streeter
  • Patent number: 9862752
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: January 9, 2018
    Assignee: Amgen Inc.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth Walker
  • Patent number: 9862753
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: January 9, 2018
    Assignees: PROCHON BIOTECH LTD., HEPACORE LTD
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Patent number: 9862754
    Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.
    Type: Grant
    Filed: October 1, 2016
    Date of Patent: January 9, 2018
    Assignee: KeyBioscience AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Patent number: 9862755
    Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: January 9, 2018
    Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
    Inventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
  • Patent number: 9862756
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: January 9, 2018
    Assignee: immatics biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 9862757
    Abstract: An inhibitor targeting specific complement, the inhibitor targeting specific complement is a protein, the protein has a targeted inhibition function on the complement activation, and the amino acid sequence of the protein comprises CRIg extracellular domain and complement inhibiting domain; the amino acid sequence of the protein is consist of the CRIg extracellular domain and the complement inhibiting domain connected directly, or indirectly through a linker which can connect the two domains. The preparation method of the inhibitor targeting specific complement comprises connecting the protein polypeptides of the CRIg extracellular domain and the complement inhibiting domain by gene engineering technology. The protein can be used to prepare a drug targeting inhibition of complement activation.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: January 9, 2018
    Assignee: FUDAN UNIVERSITY SHANGHAI CANCER CENTER
    Inventors: Weiguo Hu, Qian Qiao, Xin Zhang
  • Patent number: 9862758
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: January 9, 2018
    Assignee: BRISTOL-MYERS QUIBB COMPANY
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Patent number: 9862759
    Abstract: The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the use of an antibody library for screening monoclonal antibodies, preferably human antibodies for treating cancer.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: January 9, 2018
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Peter Lowe, Cédric Bes, Nicolas Boute
  • Patent number: 9862760
    Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: January 9, 2018
    Assignee: Novartis AG
    Inventors: Johanna Abend, Zorica Dragic, Adam Lloyd Feire, Mark Knapp, Steven Kovacs, Elisabetta Traggiai, Lichun Wang, Yongqiang Wang, Danqing Wu, Qilong Wu, Fangmin Xu
  • Patent number: 9862761
    Abstract: The present invention is a composition and method for the prevention and treatment of a tauopathy. The composition of the invention includes N-terminal amino acid residues of the tau protein, which have been identified as being involved in toxic activation of a PP1/GSK3 signaling cascade and inhibition of fast axonal transport in human tauopathies.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 9, 2018
    Assignees: The Board of Trustes of the University of Illinois, Northwestern University
    Inventors: Scott Thomas Brady, Lester I. Binder, Gerardo Andres Morfini, Nicholas M. Kanaan, Nichole E. LaPointe
  • Patent number: 9862762
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 9, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker
  • Patent number: 9862763
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 9, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Patent number: 9862764
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 9, 2018
    Assignee: NOVARTIS AG
    Inventors: Feng Cong, William Dietrich, Nathalie George, Dong Liu, Asher Schachter, Aditi Soni, Jing Zhou
  • Patent number: 9862765
    Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 9, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Lianshan Zhang, Jiajian Liu, Guoqing Cao, Piaoyang Sun
  • Patent number: 9862766
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: January 9, 2018
    Assignee: Janssen Biotech, inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9862767
    Abstract: The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 9, 2018
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Yan Yan
  • Patent number: 9862768
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: January 9, 2018
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Patent number: 9862769
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 9, 2018
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Patent number: 9862770
    Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL™ (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 9, 2018
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 9862771
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 9, 2018
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Patent number: 9862772
    Abstract: The invention relates to a composition comprising an anchor region capable of binding to a plasma cell; and a binding region associated with the anchor region, wherein the binding region binds a specific plasma cell antibody.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 9, 2018
    Assignee: BEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN (DRFZ)
    Inventors: Andreas Radbruch, Falk Hiepe, Adriano Taddeo, Velia Gerl, Bimba F. Hoyer, Hyun-Dong Chang, Andreas Theiel